TMCnet News
Research and Markets: Hemoglobinopathies - Pipeline Review, H2 2013 Research ReportDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/5z974p/hemoglobinopathies) has announced the addition of the "Hemoglobinopathies - Pipeline Review, H2 2013" report to their offering. 'Hemoglobinopathies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemoglobinopathies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemoglobinopathies. Scope - A snapshot of the global therapeutic scenario for Hemoglobinopathies. - A review of the Hemoglobinopathies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till egistration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemoglobinopathies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some Key Topics Covered: Introduction Hemoglobinopathies Overview Therapeutics Development Pipeline Products for Hemoglobinopathies - Overview Pipeline Products for Hemoglobinopathies - Comparative Analysis Hemoglobinopathies - Therapeutics under Development by Companies Hemoglobinopathies - Pipeline Products Glance Clinical Stage Products Early Stage Products Hemoglobinopathies - Products under Development by Companies Hemoglobinopathies - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target (News - Alert) Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles NiCord - Drug Profile ZFP Transcription Factors For Hemoglobinopathies - Drug Profile ALN-TMP - Drug Profile Drug Targeting PRMT5 - Drug Profile Drug Targeting Protein Arginine Methyltransferase 5 - Drug Profile Hemoglobinopathies - Recent Pipeline Updates Hemoglobinopathies - Product Development Milestones Companies Mentioned Sangamo BioSciences, Inc. Gamida Cell Ltd. Alnylam Pharmaceuticals, Inc. Cancer Therapeutics CRC Pty Ltd For more information visit http://www.researchandmarkets.com/research/5z974p/hemoglobinopathies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. |
